SCHEDULE 13G/A: BlackRock Amends Stake in Rigel Pharmaceuticals, Reports 7.7% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in Rigel Pharmaceuticals Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. filed Amendment No. 17 to Schedule 13G concerning its beneficial ownership in RIGEL PHARMACEUTICALS INC.
- As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 1,381,983 shares of Common Stock of Rigel Pharmaceuticals Inc.
- This aggregate amount represents 7.7% of the class of Rigel Pharmaceuticals Inc. Common Stock.
- BlackRock holds sole voting power over 1,368,575 shares and sole dispositive power over 1,381,983 shares.
- No shared voting power or shared dispositive power was reported.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries are identified as entities through which the securities are held, with at least one entity beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: This is a neutral, routine regulatory filing disclosing beneficial ownership. It provides no positive or negative operational or financial news about the issuer.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or BlackRock's future investment intentions beyond the certification that the shares are held in the ordinary course of business.
Industry Context
This filing reflects a routine disclosure by a major institutional asset manager, BlackRock, regarding its passive investment stake in a pharmaceutical company. Such filings are common for large investment firms that hold significant, but non-controlling, positions across various industries as part of their diversified portfolios or client mandates. It does not indicate a specific strategic move within the pharmaceutical industry but rather a compliance update on an existing investment.
Comparison to Industry Standards
- As a Schedule 13G filing, this document primarily serves as a regulatory compliance disclosure for a passive investment stake. It does not provide operational or financial results for comparison to industry standards.
- BlackRock's reported 7.7% stake in Rigel Pharmaceuticals Inc. is a significant, but not controlling, position, typical for large institutional investors managing diversified portfolios.
- There are no specific comparable companies or projects mentioned within the document to assess performance against industry benchmarks.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on a significant institutional ownership stake, which is a standard regulatory disclosure. It has no direct impact on employees, customers, suppliers, or creditors of Rigel Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously revoked Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of the event which requires the filing of this statement (reporting period end date). |
| 2025-04-17 | Date of filing/signature date of the Schedule 13G Amendment No. 17. |
Keywords
Rigel Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.